High and low EPS estimates for Roivant Sciences Ltd. (ROIV)’s current quarter

The price of Roivant Sciences Ltd. (NASDAQ: ROIV) closed at $9.22 in the last session, down -1.81% from day before closing price of $9.39. In other words, the price has decreased by -$0.17 from its previous closing price. On the day, 1897925 shares were traded. ROIV stock price reached its highest trading level at $9.33 during the session, while it also had its lowest trading level at $9.05.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.

Sponsored

Ratios:

We take a closer look at ROIV’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.70 and its Current Ratio is at 6.70. In the meantime, Its Debt-to-Equity ratio is 0.43 whereas as Long-Term Debt/Eq ratio is at 0.39.

Upgrades & Downgrades

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 09 when Venker Eric sold 238,724 shares for $9.23 per share. The transaction valued at 2,203,423 led to the insider holds 675,768 shares of the business.

Venker Eric sold 61,206 shares of ROIV for $546,570 on May 08. The President & COO now owns 675,768 shares after completing the transaction at $8.93 per share. On May 04, another insider, Venker Eric, who serves as the President & COO of the company, sold 88,838 shares for $8.30 each. As a result, the insider received 737,355 and left with 675,768 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 5.64B and an Enterprise Value of 4.59B. For the stock, the TTM Price-to-Sale (P/S) ratio is 158.24 while its Price-to-Book (P/B) ratio in mrq is 6.88. Its current Enterprise Value per Revenue stands at 106.37 whereas that against EBITDA is -3.49.

Stock Price History:

Over the past 52 weeks, ROIV has reached a high of $10.00, while it has fallen to a 52-week low of $2.87. The 50-Day Moving Average of the stock is 8.30, while the 200-Day Moving Average is calculated to be 6.56.

Shares Statistics:

According to the various share statistics, ROIV traded on average about 3.05M shares per day over the past 3-months and 2.35M shares per day over the past 10 days. A total of 713.32M shares are outstanding, with a floating share count of 440.82M. Insiders hold about 14.50% of the company’s shares, while institutions hold 51.20% stake in the company. Shares short for ROIV as of Apr 27, 2023 were 14.02M with a Short Ratio of 14.02M, compared to 13.88M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 1.85% and a Short% of Float of 8.72%.

Earnings Estimates

The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.37 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.44, while EPS last year was -$0.39. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.3 and low estimates of -$0.4.

Analysts are recommending an EPS of between -$1.34 and -$1.83 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.35, with 7 analysts recommending between -$0.86 and -$1.57.

Revenue Estimates

According to 8 analysts, the current quarter’s revenue is expected to be $20.45M. It ranges from a high estimate of $36M to a low estimate of $13M. As of the current estimate, Roivant Sciences Ltd.’s year-ago sales were $9.22M, an estimated increase of 121.70% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $22.06M, an increase of 410.80% over than the figure of $121.70% in the same quarter last year. There is a high estimate of $28.74M for the next quarter, whereas the lowest estimate is $18M.

A total of 7 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $56M, while the lowest revenue estimate was $46.9M, resulting in an average revenue estimate of $52.15M. In the same quarter a year ago, actual revenue was $55.29M, down -5.70% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $151.73M in the next fiscal year. The high estimate is $313M and the low estimate is $82.9M. The average revenue growth estimate for next year is up 190.90% from the average revenue estimate for this year.